An Indian-origin doctor pleaded guilty to illegally giving controlled substances to six patients, including one who suffered from opioid addiction and later died of a drug overdose.
Gurpreet Singh Bajwa, 49 of Fairfax, Virginia temporarily lost his medical license in 2012 following an investigation by the Virginia Department of Health Professions (DHP) into his prescription practices.
After his license was reinstated, he significantly reduced the quantity of pain medications he prescribed, and switched over to stimulants, benzodiazepines, and sedatives.
Bajwa pleaded guilty to five counts of distribution of Adderall, a combination medication containing four salts of amphetamine, and one count of distribution of oxycodone and faces a maximum penalty of 20 years in prison when sentenced on May 22.
According to court documents, generally, at no point during any of his patients' visits did Bajwa or any of his staff receive, review, or request prior medical files, obtain medical histories, conduct physical examinations, discuss the case of any attention disorder or what might properly address such a condition.
Beginning in summer 2018, two undercover law enforcement officers posed as patients and made appointments to see Bajwa.
At each visit, Bajwa prescribed the undercover officers a 30-day supply of Adderall, despite the undercover officers showing up to two weeks prior to the end of the previous 30 day period.
One of the officers told Bajwa that she was a fitness model and needed Adderall for her workouts, which is not a legitimate use for the substance.
The undercover officer also asked Bajwa to prescribe her extra pills that she could give to a friend and he readily agreed.
One of the patients to whom Bajwa prescribed significant quantities of prescription drugs had a history of high blood pressure, among other health conditions.
Nevertheless, Bajwa wrote her monthly prescriptions for the maximum dose of Adderall.
In 2016, the Centers for Disease Control and Prevention and The Food and Drug Administration issued warnings cautioning against prescribing opioids and benzodiazepines (including Xanax) together because of the increased risk of fatal overdose.
Nevertheless, on multiple occasions, Bajwa wrote prescriptions to patients for both oxycodonea powerful Schedule II opioidand Xanax.
One of Bajwa's patients, named only as NJ' in court documents, suffered from heroin addiction.
NJ's mother told Bajwa two or three times that NJ was abusing drugs, and yet Bajwa continued to prescribe controlled substances to NJ.
In November 2017, Bajwa prescribed both oxycodone and Xanax to NJ, despite knowing of NJ's drug addiction, and despite the increased danger of combining the two medications.
In January 2018, NJ was dismissed from a rehabilitation program after he was caught abusing drugs Bajwa prescribed him.
NJ died of a drug overdose a short time later.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
